Search - tctmd.com

Displaying 1 - 20 of 274

Sort: Relevancy | Date

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

Michael O'Riordan

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News CRT 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

Michael O'Riordan

March 11, 2026

News Daily News

Novel VECTOR Procedure Creates Percutaneous Aorto-Coronary Bypass

Yael L. Maxwell

January 14, 2026

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

Caitlin E. Cox

November 24, 2025

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2025

Caitlin E. Cox

November 03, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

Advertisement

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

What’s Going to Be Hot at ACC 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

Novel VECTOR Procedure Creates Percutaneous Aorto-Coronary Bypass

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

TCTMD’s Top 10 Most Popular Stories for October 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

What’s Going to Be Hot at TCT 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content